دورية أكاديمية
أعرض في EDS

Paediatric Uveitis - the uniqueness in clinical presentation and the efficacy of biologics treatment.

التفاصيل البيبلوغرافية
العنوان: Paediatric Uveitis - the uniqueness in clinical presentation and the efficacy of biologics treatment.
المؤلفون: Yiu MK; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR, China., Ho M; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR, China. maryho@cuhk.edu.hk., Ho ACH; Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China., Chan WKY; Department of Paediatrics, Queen Elizabeth Hospital, Hong Kong SAR, China., Yung W; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR, China., Yip WWK; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR, China., Young AL; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR, China.
المصدر: Journal of ophthalmic inflammation and infection [J Ophthalmic Inflamm Infect] 2024 Jul 17; Vol. 14 (1), pp. 34. Date of Electronic Publication: 2024 Jul 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 101553216 Publication Model: Electronic Cited Medium: Print ISSN: 1869-5760 (Print) Linking ISSN: 18695760 NLM ISO Abbreviation: J Ophthalmic Inflamm Infect Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Berlin : Springer
مستخلص: Aims: To evaluate unique clinical characteristics of paediatric uveitis in our locality and treatment outcomes especially the efficacy of biologics.
Methods: This was a retrospective cohort.
Results: 37 paediatric uveitis cases involving 67 eyes were included. Male-to-female ratio was 1:1.3. Mean age of uveitis onset was 11 ± 3.7 (4-18). 81.1% cases suffered from bilateral uveitis. 75.7% cases were chronic uveitis. Nearly half of the cases (40.5%) presented with anterior uveitis. The predominant diagnosis of uveitis in our cohort was idiopathic. Unlike studies from other populations, the associated systemic conditions in this mostly Chinese cohort were Behçet's disease (8.1%), tubulointerstitial nephritis and uveitis (8.1%) and HLA-B27 associated uveitis (8.1%). Steroid response was a common phenomenon, observed in 40.5% of cases. The most common complication was posterior synechiae (45.9%), followed by cataract (37.8%), glaucoma (27.0%), band keratopathy (18.9%) and macular oedema (13.5%). 3/37 patients encountered either first attack of uveitis or flare after receiving COVID-19 vaccine. 54.1% of patients required systemic steroid for disease control. The majority required steroid sparing immunotherapy, including Methotrexate (43.2%), Mycophenolate Mofetil (24.3%), Cyclosporine A (8.1%), Azathioprine (5.4%) and Tacrolimus (2.7%). Resistant cases required biologics including tumour necrosis factor alpha inhibitors (Adalimumab 32.4%, Infliximab 2.7%) and interleukin-6 inhibitors (Tocilizumab 2.7%).
Conclusions: Clinical presentation of the local paediatric uveitis differs from previously described features in Caucasian and other populations. According to our experience as a tertiary eye centre, Behçet's disease, tubulointerstitial nephritis and uveitis and HLA-B27 associated uveitis were more often encountered than Juvenile Idiopathic Arthritis associated uveitis. Our report evaluated the efficacy of immunomodulatory therapy and biologics in controlling uveitis and reducing ocular complications.
(© 2024. The Author(s).)
References: Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K, German Uveitis in Childhood Study Group (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46(6):1015–1019. https://doi.org/10.1093/rheumatology/kem053. (PMID: 10.1093/rheumatology/kem05317403710)
Ramanan AV, Dick AD, Jones AP et al (2019) Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a rct. Health Technol Assess (Rockv) 23(15):1–139. https://doi.org/10.3310/hta23150. (PMID: 10.3310/hta23150)
Smith JA, Mackensen F, Sen HN et al (2009) Epidemiology and course of Disease in Childhood Uveitis. Ophthalmology 116(8). https://doi.org/10.1016/j.ophtha.2009.05.002.
Rosenberg KD, Feuer WJ, Davis JL (2004) Ocular complications of pediatric uveitis. Ophthalmology 111(12):2299–2306. https://doi.org/10.1016/j.ophtha.2004.06.014. (PMID: 10.1016/j.ophtha.2004.06.01415582090)
Paroli MP, Restivo L, Ottaviani E et al (2022) Clinical features of infectious uveitis in children referred to a hospital-based Eye Clinic in Italy. Med (Kaunas) 58(11). https://doi.org/10.3390/medicina58111673.
Azar BSDM, Martin FRANZCOF (2004) Paediatric Uveitis: A Sydney Clinic Experience. Vol 32.
Kump LI, Cervantes-Castañeda RA, Androudi SN, Foster CS (2005) Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology 112(7):1287–1292. https://doi.org/10.1016/j.ophtha.2005.01.044. (PMID: 10.1016/j.ophtha.2005.01.04415921752)
Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–516. https://doi.org/10.1016/j.ajo.2005.03.057.
Jabs DA (2018) Immunosuppression for the Uveitides. Ophthalmology 125(2):193–202. https://doi.org/10.1016/j.ophtha.2017.08.007. (PMID: 10.1016/j.ophtha.2017.08.00728942074)
Keino H, Watanabe T, Taki W et al (2017) Clinical features of uveitis in children and adolescents at a tertiary referral centre in Tokyo. Br J Ophthalmol 101(4):406–410. https://doi.org/10.1136/bjophthalmol-2015-308194. (PMID: 10.1136/bjophthalmol-2015-30819427335142)
Ferrara M, Eggenschwiler L, Stephenson A et al (2019) The challenge of Pediatric Uveitis: Tertiary Referral Center experience in the United States. Ocul Immunol Inflamm 27(3):410–417. https://doi.org/10.1080/09273948.2017.1420202. (PMID: 10.1080/09273948.2017.142020229333911)
Shin Y, Kang JM, Lee J, Lee CS, Lee SC, Ahn JG (2021) Epidemiology of pediatric uveitis and associated systemic diseases. Pediatr Rheumatol 19(1). https://doi.org/10.1186/s12969-021-00516-2.
de Boer J, Wulffraat N, Rothova A (2003) Visual loss in uveitis of childhood. Br J Ophthalmol 87(7):879–884. https://doi.org/10.1136/bjo.87.7.879. (PMID: 10.1136/bjo.87.7.879128128911771761)
Kadayifçilar S, Eldem B, Tumer B (2003) Uveitis in childhood. J Pediatr Ophthalmol Strabismus 40(6):335–340. https://doi.org/10.3928/0191-3913-20031101-06. (PMID: 10.3928/0191-3913-20031101-0614655981)
Paroli MP, Spinucci G, Liverani M, Monte R, Pezzi PP (2009) Uveitis in childhood: an Italian clinical and epidemiological study. Ocul Immunol Inflamm 17(4):238–242. https://doi.org/10.1080/09273940802702561. (PMID: 10.1080/0927394080270256119657976)
Edelsten C, Reddy MA, Stanford MR, Graham EM (2003) Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol 135(5):676–680. https://doi.org/10.1016/S0002-9394(02)02148-7. (PMID: 10.1016/S0002-9394(02)02148-712719076)
Angeles-Han ST, McCracken C, Yeh S et al (2015) The Association of Race with Childhood Uveitis. Am J Ophthalmol 160(5):919–928e1. https://doi.org/10.1016/j.ajo.2015.08.002. (PMID: 10.1016/j.ajo.2015.08.002262555774661073)
Sun N, Wang C, Linghu W, Li X, Zhang X (2022) Demographic and clinical features of pediatric uveitis and scleritis at a tertiary referral center in China. BMC Ophthalmol 22(1):174. https://doi.org/10.1186/s12886-022-02404-z. (PMID: 10.1186/s12886-022-02404-z354368629017000)
Waduthantri S, Chee SP (2021) Pediatric Uveitis and Scleritis in a multi-ethnic Asian Population. Ocul Immunol Inflamm 29(7–8):1304–1311. https://doi.org/10.1080/09273948.2020.1766083. (PMID: 10.1080/09273948.2020.176608332643984)
Sijssens KM, Rothova A, Berendschot TTJM, de Boer JH (2006) Ocular hypertension and secondary glaucoma in children with uveitis. Ophthalmology 113(5):853–9e2. https://doi.org/10.1016/j.ophtha.2006.01.043. (PMID: 10.1016/j.ophtha.2006.01.04316650683)
Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ (2013) Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford) 52(5):825–831. https://doi.org/10.1093/rheumatology/kes186. (PMID: 10.1093/rheumatology/kes18622879466)
Sharma SM, Dick AD, Ramanan AV (2009) Non-infectious Pediatric Uveitis. Pediatr Drugs 11(4):229–241. https://doi.org/10.2165/00148581-200911040-00002. (PMID: 10.2165/00148581-200911040-00002)
Rathinam SR, Gonzales JA, Thundikandy R et al (2019) Effect of corticosteroid-sparing treatment with Mycophenolate Mofetil vs Methotrexate on inflammation in patients with Uveitis: a Randomized Clinical Trial. JAMA - J Am Med Association 322(10):936–945. https://doi.org/10.1001/jama.2019.12618. (PMID: 10.1001/jama.2019.12618)
Ramanan AV, Dick AD, Guly C et al (2020) Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol 2(3):e135–e141. https://doi.org/10.1016/S2665-9913(20)30008-4. (PMID: 10.1016/S2665-9913(20)30008-4322809507134526)
Norcia LF, Kiappe OP, Jorge EC (2021) Biological therapy in noninfectious pediatric uveitis: a systematic review. Clin Ophthalmol 15:3765–3776. https://doi.org/10.2147/OPTH.S322445. (PMID: 10.2147/OPTH.S322445345220808434856)
Maccora I, Fusco E, Marrani E, Ramanan AV, Simonini G (2021) Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatol (United Kingdom) 60(2):568–587. https://doi.org/10.1093/rheumatology/keaa595. (PMID: 10.1093/rheumatology/keaa595)
Miraldi Utz V, Angeles-Han ST, Mwase N et al (2022) Alternative biologic therapy in children failing conventional TNFα inhibitors for refractory, noninfectious, chronic anterior uveitis. Am J Ophthalmol 244:183–195. https://doi.org/10.1016/j.ajo.2022.06.024. (PMID: 10.1016/j.ajo.2022.06.02435863492)
Kreps EO, Epps SJ, Consejo A, Dick AD, Guly CM, Ramanan AV (2023) Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy. Eye Published Online Oct 17. https://doi.org/10.1038/s41433-023-02795-3.
Kam KW, Tam LS, Tam MKP, Young AL (2015) Infliximab in the treatment of Refractory Ocular Inflammatory diseases. Asia-Pacific J Ophthalmol 4(1):19–24. https://doi.org/10.1097/APO.0000000000000036. (PMID: 10.1097/APO.0000000000000036)
Ho M, Chen LJ, Sin HPY et al (2019) Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet’s disease-related uveitis. J Ophthalmic Inflamm Infect 9(1):14. https://doi.org/10.1186/s12348-019-0181-z. (PMID: 10.1186/s12348-019-0181-z313678106669227)
Ramanan AV, Dick AD, Jones AP et al (2017) Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med 376(17):1637–1646. https://doi.org/10.1056/nejmoa1614160. (PMID: 10.1056/nejmoa161416028445659)
Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):CD008794. https://doi.org/10.1002/14651858.CD008794.pub2. (PMID: 10.1002/14651858.CD008794.pub2213283097173749)
Bartelds GM, Krieckaert CLM, Nurmohamed MT et al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460–1468. https://doi.org/10.1001/jama.2011.406. (PMID: 10.1001/jama.2011.40621486979)
Sen ES, Ramanan AV (2020) Juvenile idiopathic arthritis-associated uveitis. Clin Immunol 211. https://doi.org/10.1016/j.clim.2019.108322.
Sen ES, Ramanan AV (2017) Juvenile idiopathic arthritis-associated uveitis. Best Pract Res Clin Rheumatol 31(4):517–534. https://doi.org/10.1016/j.berh.2018.01.002. (PMID: 10.1016/j.berh.2018.01.00229773271)
Ramanan AV, Dick AD, Jones AP et al (2018) A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol 2:4. https://doi.org/10.1186/s41927-018-0010-2. (PMID: 10.1186/s41927-018-0010-2308869556390576)
Maleki A, Manhapra A, Asgari S, Chang PY, Foster CS, Anesi SD (2021) Tocilizumab Employment in the treatment of resistant juvenile idiopathic arthritis Associated Uveitis. Ocul Immunol Inflamm 29(1):14–20. https://doi.org/10.1080/09273948.2020.1817501. (PMID: 10.1080/09273948.2020.181750133021415)
Chan CKM, Wu ZHY, Luk FOJ et al (2013) Clinical characteristics of intermediate uveitis in Chinese patients. Ocul Immunol Inflamm 21(1):71–76. https://doi.org/10.3109/09273948.2012.736587. (PMID: 10.3109/09273948.2012.73658723323585)
Cunningham ET (2000) Uveitis in children. Ocul Immunol Inflamm 8(4):251–261. https://doi.org/10.1076/ocii.8.4.251.6459. (PMID: 10.1076/ocii.8.4.251.645911262655)
فهرسة مساهمة: Keywords: Biologics; Immunosuppressants; Paediatric uveitis
تواريخ الأحداث: Date Created: 20240717 Latest Revision: 20240717
رمز التحديث: 20240717
DOI: 10.1186/s12348-024-00415-z
PMID: 39017721
قاعدة البيانات: MEDLINE
الوصف
تدمد:1869-5760
DOI:10.1186/s12348-024-00415-z